: A Phase IIb/III, open label, single arm, multi-centre, clinical trial to assess the safety and immunogenicity of a booster vaccination with an adapted recombinant protein RBD fusion homodimer candidate (PHH-1V81) against SARS-CoV-2, in adults vaccinated against COVID-19.

por prodriguez | Jul 3, 2024 | Ensayos Clínicos, Ensayos Clínicos - A-23 | 0 Comentarios